OSURNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
ORASURE TECHNOLOGIES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.68+0.07 (+1.94%)
Close on Oct 19, 2026
- Market cap
- $258.18M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
41.9%−17.4 pts over 5 years
Operating margin
-62.6%−59.6 pts over 5 years
Net margin
-59.8%−51.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -38.1% | -33.3% | -7.7% | -0.4% | |
| Gross profit | -39.3% | -31.3% | -13.9% | -5.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 11.4% | -4.2% | -18.3% | |
| Return on assets | 9.9% | -3.7% | -15.6% | |
| Current ratio | 9.02 | 6.21 | 6.58 | |
| Inventory turnover | 3.2× | 2.5× | 2.0× | |
| Capex to revenue | 3.4% | 15.5% | 3.6% | |
| Diluted shares | 57M | 68M | 73M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Orasure Technologies generated $300.56M from operations and spent $61.87M on capital expenditure, dividends and share buybacks. 69% of that went back into the business.
Generated
$300.56M
Used
$61.87M
Capital expenditure$42.46M69%Dividends$00%Share buybacks$19.41M31%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-59.8%
×Asset turnover0.26×
×Equity multiplier1.18×
=Return on equity, FY2025-18.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -59.8% | 0.26× | 1.18× | -18.3% |
| FY2024 | -10.5% | 0.39× | 1.14× | -4.6% |
| FY2023 | 13.2% | 0.87× | 1.17× | 13.5% |
| FY2022 | -4.4% | 0.86× | 1.22× | -4.6% |
| FY2021 | -9.8% | 0.51× | 1.18× | -5.9% |
| FY2020 | -8.7% | 0.43× | 1.14× | -4.2% |
| FY2019 | 10.8% | 0.47× | 1.13× | 5.6% |
| FY2018 | 11.2% | 0.59× | 1.13× | 7.5% |
| FY2017 | 18.5% | 0.66× | 1.14× | 13.9% |
| FY2016 | 15.4% | 0.65× | 1.15× | 11.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$68.73M
- Cash generatingOperating cash flow above zero-$49.02M
- Return on assets improvedROA up on the prior year-4.0% → -14.3%
- Earnings backed by cashOperating cash flow above net income-$49.02M vs -$68.73M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose9.95 → 6.58
- No dilutionShare count did not rise74M → 73M
- Gross margin improvedGross margin up on the prior year42.72% → 41.90%
- More efficientAsset turnover rose0.38 → 0.24